159 related articles for article (PubMed ID: 12909127)
1. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.
Gelderman KA; Hakulinen J; Hagenaars M; Kuppen PJ; Meri S; Gorter A
Mol Immunol; 2003 Sep; 40(1):13-23. PubMed ID: 12909127
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model.
Gelderman KA; Kuppen PJ; Okada N; Fleuren GJ; Gorter A
Cancer Res; 2004 Jun; 64(12):4366-72. PubMed ID: 15205353
[TBL] [Abstract][Full Text] [Related]
3. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Gelderman KA; Blok VT; Fleuren GJ; Gorter A
Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
[TBL] [Abstract][Full Text] [Related]
6. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer.
Caragine TA; Okada N; Frey AB; Tomlinson S
Cancer Res; 2002 Feb; 62(4):1110-5. PubMed ID: 11861390
[TBL] [Abstract][Full Text] [Related]
7. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
8. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
9. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Geller A; Yan J
Front Immunol; 2019; 10():1074. PubMed ID: 31164885
[TBL] [Abstract][Full Text] [Related]
10. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
12. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
13. Complement-regulatory proteins in ovarian malignancies.
Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
[TBL] [Abstract][Full Text] [Related]
14. Immune evasion of tumor cells using membrane-bound complement regulatory proteins.
Gorter A; Meri S
Immunol Today; 1999 Dec; 20(12):576-82. PubMed ID: 10562709
[TBL] [Abstract][Full Text] [Related]
15. Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity.
Caragine TA; Imai M; Frey AB; Tomlinson S
Blood; 2002 Nov; 100(9):3304-10. PubMed ID: 12384431
[TBL] [Abstract][Full Text] [Related]
16. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
[TBL] [Abstract][Full Text] [Related]
17. [The role of membrane glycoproteins CD46, CD55 and CD59 in protection of tumor cells against complement lysis].
Wojnicz D; Bar J; Jankowski S
Postepy Hig Med Dosw; 2002; 56(5):603-16. PubMed ID: 12587428
[TBL] [Abstract][Full Text] [Related]
18. [Self- and non-self recognition mechanism via the complement system].
Okada N
Nihon Rinsho; 2005 Apr; 63 Suppl 4():279-83. PubMed ID: 15861669
[No Abstract] [Full Text] [Related]
19. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells.
Quigg RJ; Morgan BP; Holers VM; Adler S; Sneed AE; Lo CF
Kidney Int; 1995 Aug; 48(2):412-21. PubMed ID: 7564108
[TBL] [Abstract][Full Text] [Related]
20. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
